Snooze alarms may cost you vital sleep — three experts weigh in on the habit
When jolted awake by the blare of an alarm clock, it's tempting to reach for the snooze button to catch a bit more shut-eye. In my case, 'just five more minutes' is practically a morning mantra. And what's the harm?
There's increasing debate about your snoozing habit, and whether or not it's silently sabotaging your morning.
On the 'stop snoozing' side of the research, sleep scientist Dr. Rebecca Robbins suggests the snooze alarm may actually cost us sleep.
'That first alarm may interrupt vital stages of sleep, and anything that you might be able to get after hitting the snooze alarm is probably going to be low quality and fragmented sleep,' said Robbins, an associate scientist for the Division of Sleep and Circadian Disorders at Brigham and Women's Hospital.
The average snoozer takes an extra 11 minutes after their first alarm, according to a new study coauthored by Robbins that used data from the sleep-tracking app SleepCycle. That adds up to about one night's worth of sleep per month spent snoozing.
As we sleep, the brain cycles through different stages of neurological activity and the second half of the night is dominated by rapid eye movement (REM) sleep, when most of our dreaming is thought to take place. It's an important sleep stage for our cognitive function and memory consolidation, said Robbins, who is also an assistant professor of medicine at Brigham and Women's Hospital.
'When you press the snooze button, especially for just a few minutes at a time, you're not likely to return to that REM stage,' Robbins said.
But for a different take, there are sleep experts like Dr. Justin Fiala, a pulmonary, critical care and sleep medicine physician at Northwestern Medicine Canning Thoracic Institute.
There isn't consensus on whether this lighter sleep achieved during a snooze session always does more harm than good, said Fiala, who is also an assistant professor at Northwestern Medicine.
On one hand, losing out on quality sleep instead of just waking up later may increase the risk of cognitive impairment and lower one's mood.
'Certainly, if you're feeling worse off (and) more tired from the snooze alarm, I would recommend going back to waking up cold turkey without it,' said Fiala, who also runs the CommunityHealth Chicago sleep clinic.
On the other hand, those with a certain chronotype — a natural disposition determined by factors such as age and genetics — may benefit from the habit, Fiala said, referencing a 2023 study which found night owls tend to rely on their snooze button more.
'If your chronotype is nocturnal, you're a night owl, but your work schedule requires you to be up at 5 a.m., that increases the dissonance between what your body is naturally inclined to do,' Fiala said.
For these night owls, the brief period of light sleep induced by the snooze button may actually help them transition from deeper stages of sleep interrupted by the first alarm into wakefulness, he said, adding that more research should be done to fully understand this effect and its limitations.
Regardless of one's chronotype, this distinction of who gets the most out of snoozing can also help inform how to get the most out of snoozing.
Consistency is key
Most sleep experts emphasize adults get the recommended 7 to 9 hours of sleep per night for good health and emotional well-being. Sleeping enough can also reduce feelings of tiredness upon waking, but the consistency of your sleep timing is just as important as duration, said Kimberly Honn, an associate professor of psychology at Washington State University Spokane.
At deep stages of sleep, electric pulses of the brain reach a highly rhythmic pattern different from our more erratic, awakened state, she explained. Trying to wake up during these stages cuts important brain maintenance processes short and can lead one to experience the foggy effects of sleep inertia, which can last for several minutes or even hours after waking up.
When the body is accustomed to a regular sleep schedule, it may reduce the experience of sleep inertia upon waking, Honn said. The body can grow accustomed to moving through each sleep stage at similar times, ensuring sleep cycles are completed before waking and eventually allowing you to fall asleep faster.
'In the perfect world, we would not be relying on an alarm clock at all,' Robbins said. 'We would be able to fall asleep and wake up naturally and have energy throughout the day.'
Fiala said he generally recommends varying bedtimes by no more than 30 minutes per night, even on weekends. If you have to switch schedules, he says you should change it incrementally over time.
Optimizing your morning routine
It's possible people who use the snooze button less simply don't have the luxury to sleep past their alarm, Robbins suggested.
Inflexible work schedules could require first responders to start their shift promptly, or parents may have to rally their children out the door and toward the school bus.
For this reason, Robbins recommends those trying to ditch a snoozing habit introduce more time constraints into their morning routine by setting the first alarm as late as possible.
'Ask yourself: Is there anything in that morning routine that you could maybe do without? Or maybe you could find a way to do it faster?' Robbins said.
Snoozing could also mean you're losing out on time that could be used for adding wakefulness-promoting habits into your morning routine.
The heaviest snoozers tracked in Robbins' study used around 22 to 27 minutes resting after the first alarm — time that could be used for stretching, journaling or cooking a nutritious breakfast, Robbins suggested.
'We talk a lot about wind down routines and bedtime rituals. I think morning rituals are also really lovely to help you get excited about your day,' Robbins said. 'It's important to find something to look forward to, whether that's a meeting in the morning, making yourself a cup of coffee, whatever helps motivate you (and) gets you out of bed.'
Timing your alarm to the sunrise and allowing natural light to come through your windows in the morning can also help signal your body to wake up, Honn said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CTV News
5 hours ago
- CTV News
Officials updating B.C. extreme heat plans annually after heat dome tragedy
It was four years ago this week that morgues were overrun by hundreds of unexpected deaths during the 2021 heat dome.


Globe and Mail
7 hours ago
- Globe and Mail
Mycosis Fungoides Pipeline Appears Robust With 4+ Key Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's, ' Mycosis Fungoides Pipeline Insight, 2025 ' report provides comprehensive insights about 4+ companies and 6+ pipeline drugs in Mycosis Fungoides pipeline landscape. It covers the Mycosis Fungoides pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Mycosis Fungoides pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the Mycosis Fungoides Pipeline. Dive into DelveInsight's comprehensive report today! @ Mycosis Fungoides Pipeline Outlook Key Takeaways from the Mycosis Fungoides Pipeline Report In June 2025, M.D. Anderson Cancer Center announced a study of ultra-low-dose-total-skin electron beam therapy with brentuximab vedotin (ULD-TSEBT+BV) among patients with stage I-IV mycosis fungoides/Sezary syndrome. In June 2025, Soligenix conducted a Phase 3 study is to evaluate the ability of an 18-week course of HyBryte and visible light to induce a Treatment Response in patients with patch/plaque phase CTCL compared to patients receiving placebo and visible study will evaluate the efficacy and safety of HyBryte (0.25% hypericin) gel or placebo gel applied twice weekly for 18 weeks. Treated lesions will be covered with opaque material (such as opaque clothing), followed 21 (±3) hours later by the administration of visible light. All of the participant's lesions that are readily available for exposure to the visible light source will be treated and 3 to 5 index lesions in each patient will be prospectively identified and documented for modified Composite Assessment of Index Lesion Severity (mCAILS) evaluation. Participants will be followed every 4 weeks for a total of 12 weeks following their last light session. DelveInsight's Mycosis Fungoides Pipeline report depicts a robust space with 3+ active players working to develop 3+ pipeline therapies for Mycosis Fungoides treatment. The leading Mycosis Fungoides Companies such as Innate Pharma, Soligenix, Bristol-Myers Squibb and others. Promising Mycosis Fungoides Pipeline Therapies such as Brentuximab vedotin, mechlorethamine-MCH (nitrogen mustard), Hypericin, Ritlecitinib, Methoxsalen+ECP, AFM13 and others. Stay ahead with the most recent pipeline outlook for Mycosis Fungoides. Get insights into clinical trials, emerging therapies, and leading companies with Mycosis Fungoides @ Mycosis Fungoides Treatment Drugs Mycosis Fungoides Emerging Drugs Profile Hypericin: Soligenix HyBryte™ (research name SGX301) is a novel, first-in-class, photodynamic therapy utilizing safe, visible light for activation. The active ingredient in HyBryte™ is synthetic hypericin, a potent photosensitizer that is topically applied to skin lesions that is taken up by the malignant T-cells, and then activated by safe, visible light approximately 24 hours later. The use of visible light in the red-yellow spectrum has the advantage of penetrating more deeply into the skin (much more so than ultraviolet light) and therefore potentially treating deeper skin disease and thicker plaques and lesions. This treatment approach avoids the risk of secondary malignancies (including melanoma) inherent with the frequently employed DNA-damaging drugs and other phototherapy that are dependent on ultraviolet exposure. Combined with photoactivation, hypericin has demonstrated significant anti-proliferative effects on activated normal human lymphoid cells and inhibited growth of malignant T-cells isolated from CTCL patients. Currently, the drug is in Phase III stage of its development for the treatment of Mycosis Fungoides. IPH4102: Innate Pharma Lacutamab (IPH4102) is a first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is currently in clinical trials for treatment of cutaneous T-cell lymphoma (CTCL), an orphan disease, and peripheral T cell lymphoma (PTCL). Lacutamab has been granted U.S. FDA Breakthrough Therapy Designation for relapsed or refractory Sézary syndrome. Innate Pharma SA announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to lacutamab, an anti-KIR3DL2 cytotoxicity-inducing antibody, for the treatment of adult patients with relapsed or refractory (r/r) Sézary syndrome (SS) after at least 2 prior systemic therapies including mogamulizumab. Currently, the drug is in Phase II stage of its development for the treatment of Mycosis Fungoides. The Mycosis Fungoides Pipeline Report Provides Insights into- The report provides detailed insights about companies that are developing therapies for the treatment of Mycosis Fungoides with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Mycosis Fungoides Treatment. Mycosis Fungoides Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Mycosis Fungoides Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Mycosis Fungoides market Explore groundbreaking therapies and clinical trials in the Mycosis Fungoides Pipeline. Access DelveInsight's detailed report now! @ New Mycosis Fungoides Drugs Mycosis Fungoides Companies Innate Pharma, Soligenix, Bristol-Myers Squibb and others. Mycosis Fungoides pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical Mycosis Fungoides Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Unveil the future of Mycosis Fungoides Treatment. Learn about new drugs, Mycosis Fungoides Pipeline developments, and key companies with DelveInsight's expert analysis @ Mycosis Fungoides Market Drivers and Barriers Scope of the Mycosis Fungoides Pipeline Report Coverage- Global Mycosis Fungoides Companies- Innate Pharma, Soligenix, Bristol-Myers Squibb and others. Mycosis Fungoides Pipeline Therapies- Brentuximab vedotin, mechlorethamine-MCH (nitrogen mustard), Hypericin, Ritlecitinib, Methoxsalen+ECP, AFM13 and others. Mycosis Fungoides Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Mycosis Fungoides Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Get the latest on Mycosis Fungoides Pipeline Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Mycosis Fungoides Companies, Key Products and Unmet Needs Table of Contents Introduction Executive Summary Mycosis Fungoides: Overview Pipeline Therapeutics Therapeutic Assessment Mycosis Fungoides– DelveInsight's Analytical Perspective Late Stage Products (Phase III) Hypericin: Soligenix Drug profiles in the detailed report….. Mid Stage Products (Phase II) IPH4102: Innate Pharma Drug profiles in the detailed report….. Early Stage Products (Phase I) Drug Name: Company Name Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug Name: Company Name Inactive Products Mycosis Fungoides Key Companies Mycosis Fungoides Key Products Mycosis Fungoides- Unmet Needs Mycosis Fungoides- Market Drivers and Barriers Mycosis Fungoides- Future Perspectives and Conclusion Mycosis Fungoides Analyst Views Mycosis Fungoides Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:


Globe and Mail
9 hours ago
- Globe and Mail
Dr. Michael Rimlawi Announces National Scholarship Opportunity for Aspiring Physicians Through the 'Dr. Michael Rimlawi Scholarship for Future Doctors'
Dr. Michael Rimlawi Announces National Scholarship Opportunity for Aspiring Physicians Through the 'Dr. Michael Rimlawi Scholarship for Future Doctors' Dallas, Texas - The Dr. Michael Rimlawi Scholarship for Future Doctors is now open for applications, offering a meaningful academic opportunity to undergraduate students across the United States who are committed to pursuing a career in medicine. Spearheaded by renowned spine surgeon Dr. Michael Rimlawi, this scholarship reflects a deep commitment to supporting the next generation of healthcare leaders who are ready to make a difference in the field of medicine. The scholarship is designed for undergraduate students enrolled at accredited colleges or universities who have set their sights on a future in healthcare. In line with Dr. Michael Rimlawi's dedication to innovation and mentorship in the medical field, the program encourages thoughtful reflection on personal inspiration and the impact future doctors wish to have in the profession. To be considered, applicants must submit an original essay between 500 and 750 words responding to the prompt: 'What inspired you to pursue a career in medicine, and how do you hope to make a difference in the field?' Essays will be evaluated on clarity, originality, and depth of insight. The deadline for application submissions is January 15, 2026, and the scholarship recipient will be announced on February 15, 2026. Dr. Michael Rimlawi, who is widely respected for his pioneering contributions in minimally invasive spine surgery, brings both clinical excellence and visionary leadership to the scholarship initiative. As a physician who has led advancements in micro-endoscopic techniques and was the first in the nation to perform the Globus Minimally Invasive XLIF procedure, Dr. Rimlawi understands the transformative impact of dedication and continuous learning in medicine. Through this scholarship, Dr. Michael Rimlawi aims to help lessen the financial burden for students who demonstrate not only academic determination but also a clear vision for how they intend to shape the healthcare system in meaningful ways. The scholarship is not limited by geographic region and is open to qualified undergraduate students throughout the United States. 'Mentoring future doctors has always been a personal mission,' says Dr. Michael Rimlawi, who has long advocated for educational support as a means to uplift future medical professionals. By launching this scholarship, Dr. Michael Rimlawi seeks to provide more than financial aid—he offers recognition and encouragement to students committed to advancing patient-centered care. The Dr. Michael Rimlawi Scholarship for Future Doctors continues to grow as an extension of Dr. Rimlawi's broader mission: to foster innovation, compassion, and progress within the healthcare system by investing in students who will become the physicians of tomorrow. Applicants interested in this opportunity are encouraged to visit the official website to review the full eligibility criteria and submit their essays through the application portal. For more details or to apply, visit below. Media Contact Company Name: Dr. Michael Rimlawi Scholarship Contact Person: Dr. Michael Rimlawi Email: Send Email City: Dallas State: Texas Country: United States Website: